CN102940693A - 治疗糖尿病足的药物组合物 - Google Patents
治疗糖尿病足的药物组合物 Download PDFInfo
- Publication number
- CN102940693A CN102940693A CN2012104286418A CN201210428641A CN102940693A CN 102940693 A CN102940693 A CN 102940693A CN 2012104286418 A CN2012104286418 A CN 2012104286418A CN 201210428641 A CN201210428641 A CN 201210428641A CN 102940693 A CN102940693 A CN 102940693A
- Authority
- CN
- China
- Prior art keywords
- parts
- diabetic foot
- radix
- carapax
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 208000008960 Diabetic foot Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 241000245240 Lonicera Species 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000270708 Testudinidae Species 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 238000005469 granulation Methods 0.000 description 14
- 230000003179 granulation Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- 239000012467 final product Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000002266 amputation Methods 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012665 Diabetic gangrene Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210428641.8A CN102940693B (zh) | 2012-10-31 | 2012-10-31 | 治疗糖尿病足的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210428641.8A CN102940693B (zh) | 2012-10-31 | 2012-10-31 | 治疗糖尿病足的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102940693A true CN102940693A (zh) | 2013-02-27 |
CN102940693B CN102940693B (zh) | 2014-07-23 |
Family
ID=47723753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210428641.8A Active CN102940693B (zh) | 2012-10-31 | 2012-10-31 | 治疗糖尿病足的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102940693B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104352672A (zh) * | 2014-11-11 | 2015-02-18 | 成都华熹科技有限公司 | 一种含龟板的治疗糖尿病的中药组合物 |
CN104367631A (zh) * | 2014-11-13 | 2015-02-25 | 成都医路康医学技术服务有限公司 | 一种含有龟板的治疗糖尿病足的中药组合物 |
CN112220905A (zh) * | 2020-11-13 | 2021-01-15 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | 一种用于治疗糖尿病痛性神经病变的中药制剂 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009001362A2 (en) * | 2007-06-28 | 2008-12-31 | Ascarit Ltd | Herbal compositions for the treatment of diabetes and/or conditions associated therewith |
US7682617B2 (en) * | 2005-11-10 | 2010-03-23 | Jose Angel Olalde Rangel | Synergistic phytoceutical compositions |
CN101675970A (zh) * | 2008-09-16 | 2010-03-24 | 倪海军 | 一种治疗糖尿病的纯中药制剂 |
CN101757159A (zh) * | 2008-11-18 | 2010-06-30 | 姜晓宇 | 辅助治疗糖尿病的足浴液 |
WO2012059926A1 (en) * | 2010-11-07 | 2012-05-10 | Skin Matrix Ltd. | Plant extracts for treating burns and chronic wounds |
CN102697939A (zh) * | 2012-07-03 | 2012-10-03 | 山东省千佛山医院 | 一种预防糖尿病足的中药足浴液及其制备方法 |
-
2012
- 2012-10-31 CN CN201210428641.8A patent/CN102940693B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7682617B2 (en) * | 2005-11-10 | 2010-03-23 | Jose Angel Olalde Rangel | Synergistic phytoceutical compositions |
WO2009001362A2 (en) * | 2007-06-28 | 2008-12-31 | Ascarit Ltd | Herbal compositions for the treatment of diabetes and/or conditions associated therewith |
CN101675970A (zh) * | 2008-09-16 | 2010-03-24 | 倪海军 | 一种治疗糖尿病的纯中药制剂 |
CN101757159A (zh) * | 2008-11-18 | 2010-06-30 | 姜晓宇 | 辅助治疗糖尿病的足浴液 |
WO2012059926A1 (en) * | 2010-11-07 | 2012-05-10 | Skin Matrix Ltd. | Plant extracts for treating burns and chronic wounds |
CN102697939A (zh) * | 2012-07-03 | 2012-10-03 | 山东省千佛山医院 | 一种预防糖尿病足的中药足浴液及其制备方法 |
Non-Patent Citations (1)
Title |
---|
吉文晶等: "中医药治疗糖尿病足的临床研究概况", 《江西中医药》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104352672A (zh) * | 2014-11-11 | 2015-02-18 | 成都华熹科技有限公司 | 一种含龟板的治疗糖尿病的中药组合物 |
CN104367631A (zh) * | 2014-11-13 | 2015-02-25 | 成都医路康医学技术服务有限公司 | 一种含有龟板的治疗糖尿病足的中药组合物 |
CN112220905A (zh) * | 2020-11-13 | 2021-01-15 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | 一种用于治疗糖尿病痛性神经病变的中药制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN102940693B (zh) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102940693B (zh) | 治疗糖尿病足的药物组合物 | |
CN1907394B (zh) | 一种治疗糖尿病足的药物 | |
CN1247231C (zh) | 一种产后补血保健药物及其制备方法和应用 | |
CN102940757B (zh) | 治疗糖尿病足的药物组合物 | |
CN102940743B (zh) | 治疗糖尿病足的药物组合物 | |
CN102940677B (zh) | 治疗糖尿病足的药物组合物 | |
CN104689132A (zh) | 一种治疗银屑病的中药组合物 | |
CN102188679B (zh) | 一种治疗气血虚弱型冻伤的中药制备方法 | |
CN104548029A (zh) | 一种治疗胃脘痛的药物组合物 | |
CN107468857A (zh) | 一种能够治疗胃溃疡的中药制备方法 | |
CN1284593C (zh) | 一种治疗过敏性紫癜的药 | |
CN102940671B (zh) | 治疗糖尿病足的药物组合物 | |
CN101829188B (zh) | 一种治疗泌尿系感染和结石病的药物 | |
CN104095915A (zh) | 一种治疗糖尿病足的中药组合物 | |
CN108743885A (zh) | 一种治疗糖尿病大血管病变的中药及其制备方法 | |
CN103157091A (zh) | 一种治疗烧烫伤的药剂 | |
CN106581468A (zh) | 一种能够治疗胃溃疡的中药制备方法 | |
CN101391045B (zh) | 一种治疗偏正头痛的中药复方制剂及其制备方法 | |
CN101912566B (zh) | 治疗心悸的中药 | |
CN103860899B (zh) | 一种治疗糖尿病足的中药组合物 | |
CN101890069A (zh) | 预防和治疗痛风病的药物及其制备工艺 | |
CN104435167A (zh) | 一种含有土元的治疗糖尿病足的中药组合物 | |
CN104435497A (zh) | 一种治疗糖尿病足的中药组合物 | |
CN104435979B (zh) | 一种治疗风湿腰腿疼痛的药物 | |
CN117959394A (zh) | 参芪通脉制剂在制备防治糖尿病神经病变药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANTONG YUEYUE INDUSTRY CO., LTD. Free format text: FORMER OWNER: CHENGDU YILUKANG MEDICAL TECHNOLOGY SERVICE CO., LTD. Effective date: 20150317 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 226131 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150317 Address after: 226131 Jiangsu city of Nantong Province Haimen Yuelai town Fuxing Road, building 12, the town government compound Patentee after: NANTONG LEYUE INDUSTRIAL LTD. Address before: Science Park high tech Zone of Chengdu South Road, No. 88 610041 Sichuan province Tianfu Life Science Park building B6 No. 9 Patentee before: CHENGDU YILUKANG MEDICAL TECHNOLOGY & SERVICE Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220402 Address after: 100000 west 2, 1st floor, building 12, Liyuan B District, Huangcun Town, Daxing District, Beijing Patentee after: Beijing Shengshou Miao medical hall Enterprise Management Co.,Ltd. Address before: 226131 Government Courtyard, Building 12, Fuxing Road, Yuelai Town, Haimen City, Nantong City, Jiangsu Province Patentee before: NANTONG LEYUE INDUSTRIAL LTD. |
|
CP02 | Change in the address of a patent holder |
Address after: No. 212, Building 5, Bottom Business, Tongguan District 1, Majuqiao Town, Daxing District Economic and Technological Development Zone (Tongzhou), Beijing 101100 Patentee after: Beijing Shengshou Miao medical hall Enterprise Management Co.,Ltd. Address before: 100000 west 2, 1st floor, building 12, Liyuan B District, Huangcun Town, Daxing District, Beijing Patentee before: Beijing Shengshou Miao medical hall Enterprise Management Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |